Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 438-444

  Dilger, Karin ^a   Zheng, Zhichang ^a   Klotz, Ulrich ^a  

^a ROBERT BOSCH GMBH   (Germany)

Author keywords

Cytochrome P4501A2; Drug interaction; Proton pump inhibitors; Theophylline

Indexed keywords

BRONCHODILATING AGENT; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENACETIN O DEETHYLASE; PROTON PUMP INHIBITOR; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; ENZYME INDUCTION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; THEOPHYLLINE;

EID: 0032868028     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00043.x     Document Type: Article

References (52)

1. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49.
2. Fitton A, Wisemann L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-482.
3. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drags 1997; 54: 473-500.
4. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitor. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
5. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
6. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212.
7. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991; 36: 1665-1669.
8. Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.
9. Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: An in vitro investigation using human liver microsomes. Br J Clin Pharmacol 1996; 42: 157-162.
10. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8: 33-38.
11. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79-85.
12. Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-747.
13. McDonnell WM, Scheimann JM, Traber PG. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 1992; 103: 1509-1516.
14. Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269: 384-392.
15. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-411.
16. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatot 1996; 8: S21-S25.
17. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34: 243-262.
18. Andersson T. Holmberg J, Röhss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the protonpump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-375.
19. Rizzo N, Padoin C, Palombo S, Scherrmann JM, Girre C. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996; 49: 491-495.
20. Hartmann M, Blicsath H, Zech K, et al. Lack of induction of CYP1A2 activity in man by pantoprazole. Gut 1995; 37: A32.
21. Vassallo R, Lipsky JJ. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998; 73: 346-354.
22. Sarkar MA, Jackson BJ. Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 1994; 22: 827-834.
23. Zhang Z, Kaminsky LS. Characterisation of human cytochromes P450 involved in theophylline 8 hydroxylation. Biochem Pharmacol 1995; 50: 205-211.
24. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276: 912-917.
25. Vesell ES. The model drug approach in clinical pharmacology. Clin Pharmacol Ther 1991; 50: 239-248.
26. Kivistö KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40S-48S.
27. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-459.
28. Jonkman JHG, Upton RA. Pharmacokinetic drug interactions with theopbylline. Clin Pharmacokinet 1984; 9: 309-334.
29. 2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmac Ther 1987; 33: 133-137.
30. Oosterhuis B, Jonkman JHG, Andersson T, Zuiderwijk PBM. No influence of single intravenous doses of omeprazole in theophylline elimination kinetics. J Clin Pharmacol 1992; 32: 470-475.
31. Schulz HU. Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1996; 34: S51-S57.
32. Pilotto A, Franceschi M, Lagni M, et al. The effect of omeprazole on serum concentrations of theophylline, pepsinogens A and C, and gastrin in elderly duodenal ulcer patients. Am J Ther 1995; 2: 43-46.
33. Taburet AM. Geneve J, Bocquentin M, Simoneau G, Caulin C, Singlas E. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol 1992; 42: 343-345.
34. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391-395.
35. Grannemann GR, Karol MD, Locke CS, Cavanaugh JH. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460-464.
36. Sanz EJ, Villen T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
37. Fuchs WS, von Nieciecki A, Molz KH, et al. Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation. Drug Res 1996; 46: 1120-1126.
38. Conney AH, Pantuck FJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20: 633-642.
39. Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 88-95.
40. Vistisen K, Poulsen HE, Loft S. Foreign compouod metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561-1568.
41. Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther 1997; 11: 711-718.
42. Heinzel G, Woloszczak R, Thomann P. TopFit, Version 2.0: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC New York: Gustav Fischer 1993.
43. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 29: 323-328.
44. Kashuba ADM, Bertino JS, Kearns G, et al. Quantification of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYPlA2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998; 63: 540-551.
45. Weinberger M, Hendeles L, Theophylline in asthma. N Engl J Med 1996; 334: 1380-1388.
46. Skorodin MS. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Arch Intern Med 1993; 153: 814-828.
47. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159-161.
48. Wilson CG, Washington N, Greaves JL, et al. Effect of pretreatment with ranitidine on the pharmacokinetics and gastrointestinal transit of a sustained release theophylline preparation. Drug Res 1991; 41: 1154-1159.
49. Schall R, Hundt HKL, Luus HG. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 1994; 32: 633-637.
50. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 157-167.
51. Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 391-398.
52. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: S7-S16.